See more : CSE Global Limited (CSYJF) Income Statement Analysis – Financial Results
Complete financial analysis of ImmunityBio, Inc. (IBRX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ImmunityBio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Lode-Star Mining Inc. (LSMG) Income Statement Analysis – Financial Results
- Mountain Energy Inc (MTEI) Income Statement Analysis – Financial Results
- Rojana Industrial Park Public Company Limited (RJIFF) Income Statement Analysis – Financial Results
- Research Frontiers Incorporated (REFR) Income Statement Analysis – Financial Results
- PT Indofood Sukses Makmur Tbk (INDF.JK) Income Statement Analysis – Financial Results
ImmunityBio, Inc. (IBRX)
About ImmunityBio, Inc.
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers, as well as pathogens as SARS-CoV-2 and HIV. It has collaboration agreements with National Cancer Institute, National Institute of Deafness and Communication Disorders, and Amyris, Inc.; and license agreements with CytRx Corporation, EnGeneIC Pty Limited, GlobeImmune, Inc., and Infectious Disease Research Institute, Sanford Health, Shenzhen Beike Biotechnology Co. Ltd., Sorrento Therapeutics, Inc., and Viracta Therapeutics, Inc. The company was founded in 2014 and is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 622.00K | 240.00K | 934.00K | 605.00K | 2.20M | 47.00K | 45.00K | 44.00K | 236.00K | 641.00K | 600.00K |
| Cost of Revenue | 0.00 | 24.19M | 0.00 | 9.15M | 9.01M | -3.11M | 0.00 | 0.00 | 0.00 | 0.00 | 253.00K |
| Gross Profit | 622.00K | -23.95M | 934.00K | -8.54M | -6.81M | 3.16M | 45.00K | 44.00K | 236.00K | 641.00K | 347.00K |
| Gross Profit Ratio | 100.00% | -9,980.00% | 100.00% | -1,411.90% | -309.26% | 6,717.02% | 100.00% | 100.00% | 100.00% | 100.00% | 57.83% |
| Research & Development | 232.37M | 248.15M | 195.96M | 139.51M | 112.00M | 53.42M | 39.78M | 26.55M | 11.43M | 1.60M | 446.00K |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 28.39M | 57.12M | 95.39M | 227.68M | 4.33M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.07M | -3.30M | -1.00M | -1.47M | 0.00 | 0.00 |
| SG&A | 129.62M | 102.71M | 135.26M | 71.32M | 46.46M | 35.46M | 53.82M | 94.39M | 226.21M | 4.33M | 2.42M |
| Other Expenses | 886.00K | -736.00K | 193.00K | 1.49M | -534.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 362.87M | 350.86M | 331.21M | 210.83M | 158.45M | 88.88M | 93.60M | 120.94M | 237.64M | 5.92M | 2.87M |
| Cost & Expenses | 362.87M | 350.86M | 331.21M | 210.83M | 158.45M | 98.44M | 99.17M | 124.54M | 239.11M | 6.24M | 2.87M |
| Interest Income | 863.00K | 2.71M | 836.00K | 1.73M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.00K |
| Interest Expense | 129.20M | 63.52M | 14.85M | 9.07M | 5.92M | 433.00K | 618.00K | 66.00K | 0.00 | 0.00 | 463.00K |
| Depreciation & Amortization | 18.51M | 24.19M | 19.12M | 9.15M | 9.01M | 9.56M | 5.57M | 3.61M | 1.47M | 128.00K | 4.00K |
| EBITDA | -436.18M | -335.51M | -315.38M | -187.93M | -142.27M | -86.74M | -90.73M | -117.71M | -235.71M | -5.68M | -1.58M |
| EBITDA Ratio | -70,125.72% | -143,324.17% | -33,865.52% | -32,252.56% | -6,356.77% | -189,008.51% | -207,897.78% | -274,756.82% | -100,594.92% | -949.14% | -263.17% |
| Operating Income | -362.25M | -351.30M | -330.28M | -220.88M | -156.25M | -98.39M | -99.12M | -124.50M | -238.88M | -6.21M | -2.27M |
| Operating Income Ratio | -58,239.55% | -146,374.17% | -35,361.88% | -36,509.09% | -7,095.87% | -209,338.30% | -220,266.67% | -282,954.55% | -101,218.64% | -969.11% | -378.17% |
| Total Other Income/Expenses | -221.64M | -65.99M | -19.56M | -25.36M | -3.95M | 1.66M | 2.20M | 3.12M | 1.70M | -609.00K | 223.00K |
| Income Before Tax | -583.89M | -417.29M | -349.84M | -226.03M | -160.26M | -96.73M | -96.92M | -121.38M | -237.18M | -6.21M | -2.05M |
| Income Before Tax Ratio | -93,873.31% | -173,869.17% | -37,456.00% | -37,360.83% | -7,278.07% | -205,806.38% | -215,368.89% | -275,865.91% | -100,498.73% | -969.11% | -341.00% |
| Income Tax Expense | -40.00K | 34.00K | 9.00K | -1.85M | -105.00K | -503.00K | -493.00K | -572.00K | -301.00K | 1.00K | 1.00K |
| Net Income | -583.20M | -417.32M | -349.85M | -224.19M | -160.16M | -96.23M | -96.42M | -120.81M | -236.88M | -6.21M | -2.05M |
| Net Income Ratio | -93,761.41% | -173,883.33% | -37,456.96% | -37,055.70% | -7,273.30% | -204,736.17% | -214,273.33% | -274,565.91% | -100,371.19% | -969.27% | -341.17% |
| EPS | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 | -1.20 | -1.47 | -3.31 | -0.02 | -2.57 |
| EPS Diluted | -1.15 | -1.04 | -0.90 | -0.59 | -0.42 | -1.22 | -1.20 | -1.47 | -3.31 | -0.02 | -2.57 |
| Weighted Avg Shares Out | 508.64M | 399.90M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
| Weighted Avg Shares Out (Dil) | 508.64M | 399.90M | 389.23M | 383.18M | 383.18M | 79.13M | 80.58M | 81.98M | 71.52M | 315.73M | 797.11K |
Why Shares of ImmunityBio Jumped This Week
The clinical-stage biotech's lead therapy is in trials to treat bladder cancer. The sale of company stock helped raise $470 million.
ImmunityBio Announces $470 Million Equity and Debt Financing From Founder, Dr. Patrick Soon-Shiong and Nant Entities
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced that it has executed financing transactions resulting in approximately $200 million of proceeds to the Company through a financing including an exchange into equity of current debt...
IBRX DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before Important August 29 Deadline in Securities Class Action – IBRX
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between May 23, 2022 and May 10, 2023, both dates inclusive (the “Class Period”), of the important August 29,...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of ImmunityBio, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of August 29, 2023 - (NASDAQ: IBRX)
NEW YORK , Aug. 29, 2023 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of ImmunityBio, Inc.. Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible...
FINAL DEADLINE TODAY: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of §§10(b) and...
3 Very Oversold Biotech Stocks to Buy Right Now
After I spent many years following Wall Street, there are a few characteristics about the “big money” that stand out for me. One of these traits is that many if not most large investors are very reluctant to buy stocks...
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against ImmunityBio, Inc. (IBRX)
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 29, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired ImmunityBio, Inc. (“ImmunityBio” or the...
SHAREHOLDER ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of August 29, 2023 in the Class Action Filed on Behalf of ImmunityBio, Inc. (IBRX) Shareholders
NEW YORK , Aug. 28, 2023 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of ImmunityBio, Inc. (NASDAQ: IBRX) alleging that the Company violated federal securities laws. Class Period:...
AUGUST 29 FINAL DEADLINE: The Schall Law Firm Encourages Investors in ImmunityBio, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / August 28, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ImmunityBio, Inc. ("ImmunityBio" or "the Company") (NASDAQ:IBRX) for violations of §§10(b) and...
SHAREHOLDER ALERT: Levi & Korsinsky Notifies ImmunityBio, Inc.(IBRX) Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Aug. 24, 2023 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in ImmunityBio, Inc. ("ImmunityBio" or the "Company") (NASDAQ: IBRX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of...
Source: https://incomestatements.info
Category: Stock Reports